arrow
K

Kouichi Miura

jichi medical university
H指数:27
被引数:4,797

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world efficacy and safety of avatrombopag in Japanese patients with chronic liver disease and severe thrombocytopenia

阿伐曲泊帕在日本慢性肝病合并重度血小板减少症患者中的真实世界有效性与安全性

2026-07-300
PRE
Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study

索磷布韦/维帕他韦治疗丙型肝炎病毒相关失代偿期肝硬化的长期疗效:一项回顾性多中心队列研究

2026-04-010
PRE
Microbiota-mediated induction of beige adipocytes in response to dietary cues

微生物群介导的米色脂肪细胞对饮食线索的诱导

Nature
IF48.5
2026-03-040
OAAI
Inhibition of 7-dehydrocholesterol reductase prevents hepatic ferroptosis under an active state of sterol synthesis
2024-03-1211
OAAI
Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence

血清MYCN作为预测预后和治疗反应的生物标志物在预防肝细胞癌复发中的作用

2024-02-212
OA
Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease
2023-03-077
PRE
SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum
2022-12-0514
OAAI
Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study

CREB结合蛋白/β-catenin抑制剂OP-724晚期原发性胆汁性胆管炎患者的可行性、安全性和耐受性: 研究者发起的、开放标签、非随机、双中心、1期研究

2022-11-286
OAAI